Sales and Marketing

Showing 15 posts of 11527 posts found.

EMA clarifies antibodies development

June 20, 2012 Manufacturing and Production, Research and Development, Sales and Marketing CMPHU, EMA, RA, antibodies

European regulators have issued final guidance on how pharma manufacturers should develop drugs containing monoclonal antibodies. Typically used in treatments …

Life appoints new digital director

June 20, 2012 Business Services, Medical Communications, Sales and Marketing Life, digital director

Life Healthcare Communications has appointed a new digital director to head up its expanding digital department. Francesco Raimo joins Life …

Merck KGaA confirms leadership team appointments

June 20, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMD Serono, Merck KGaA, Serono

The subsidiary of Merck KGaA named EMD Serono has announced several appointments to its leadership team. The appointments include: Allene …

Storm clouds gathering over the NHS, say its leaders

June 20, 2012 Sales and Marketing Mike Farrar, NHS Confederation, NHS reforms, reforms

NHS managers are using their annual conference to criticise the government’s savings programmes. The government is looking to make £20 …

Roche signs research deal on autism spectrum disorders

June 19, 2012 Research and Development, Sales and Marketing ASD, FXS, Roche, Seaside Therapeutics, asperger's, autism

Roche has signed an agreement with Seaside Therapeutics to develop new treatments for autism and other neurodevelopmental conditions such as …

Senates and networks – do they have a role in the new NHS?

June 19, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, health forum, reforms, senates and networks

The recent Westminster Health Forum meeting on ‘Developing Clinical Senates and Networks’ focused on one aspect of the new NHS …

FDA holds up Pfizer’s rare disease drug tafamidis

June 19, 2012 Research and Development, Sales and Marketing FDA, Pfizer, rare disease, tafamidis

The FDA has sent Pfizer a Complete Response Letter about its rare disease drug tafamidis meglumine. The US regulator is …

GSK partners with Cambridge University

June 18, 2012 Research and Development, Sales and Marketing ABPI, Cambridge, GSK, R&D

The University of Cambridge begins a new collaboration with GlaxoSmithKline today to advance drug discovery and the development of new …

PMCPA reprimands Chiesi for multiple breaches

June 18, 2012 Sales and Marketing COPD, Chiesi, GSK, PMCPA, code

Chiesi has been publicly reprimanded by the PMCPA part for promoting its asthma drug Fostair off-label. The embarrassing slapdown from …

New director appointments to the NHS Commissioning Board

June 18, 2012 Medical Communications, Sales and Marketing Lansley, NHS, reforms

Lord Adebowale, Margaret Casely-Hayford, Dame Moira Gibb and Naguib Kheraj have been confirmed as four new non-executive directors of the …

Janssen looks to broaden Zytiga licence

June 18, 2012 Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate

Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …

New director of market access at Celgene UK and Ireland

June 18, 2012 Business Services, Medical Communications, Sales and Marketing Celgene, Nicola Redfern, oncology

Celgene has announced the appointment of Nicola Redfern as director of market access, Celgene UK and Ireland. Redfern brings a …

Lundbeck to slash 600 jobs in Europe

June 15, 2012 Sales and Marketing Cipralex, Europe, Lundbeck, austerity, cuts

Lundbeck will cut 600 jobs from its operations in Europe as its Cipralex parent expiry continues to erode revenue. The …

NICE launches new BNF prescribing app

June 15, 2012 Medical Communications, Sales and Marketing BNF, NICE, app, digital, pharma

NICE has launched a new app that allows users to search all medicines listed in the British National Formulary. The …

Merck’s sleep aid drug meets goals

June 15, 2012 Research and Development, Sales and Marketing FDA, Merck, insomnia, sleep disorder, suvorexant

Merck’s novel insomnia drug suvorexant has improved patients’ ability to fall asleep, according to new data from two Phase III …
The Gateway to Local Adoption Series

Latest content